AriBioLab
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aribiolab develops vaccines and immunotherapies designed to trigger stronger immune responses against infectious diseases, chronic conditions such as hepatitis B, and cancer.
Its core technology is a proprietary adjuvant platform, adjuvants are substances added to vaccines to amplify the body's immune reaction, built around two formulations, L-pampo® and Lipo-pam®. The company's pipeline centres on a therapeutic hepatitis B vaccine, an improved shingles vaccine, an elderly-focused influenza vaccine, a norovirus vaccine, and cancer vaccines. It is listed on KOSDAQ, South Korea's technology and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
The filing states that the controlling shareholder became CHA Biotech Co., Ltd., placing Aribiolab within the Cha Hospital/Cha Bio Group.
AriBioLab in five facts
What does AriBioLab do?
Aribiolab develops vaccines and immunotherapies designed to trigger stronger immune responses against infectious diseases, chronic conditions such as hepatitis B, and cancer.
Where is AriBioLab listed and in which sector?
AriBioLab (Korean name: 아리바이오랩) trades under KRX code 261780 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is AriBioLab?
Its market capitalisation was US$87.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were AriBioLab's latest annual revenue and operating profit?
For fiscal year 2025, AriBioLab reported revenue of US$119.7K, an operating loss of US$10.8M and a net loss of US$12.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 57.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Securities issuance results (voluntary)Oct 16
- Material event report (decision to sell own convertible bonds)Capital raise · Oct 16
- Material management matter relevant to investment decisionsOct 6
- DisclosureSep 29
- [Amended] Material event report (convertible bonds)
AriBioLab updated the terms of convertible bonds to raise US$2.94M, about 3.7% of its market value.
Capital raise · Sep 28 - Securities issuance results (voluntary)Sep 22
- [Amended] Material event report (convertible bonds)
AriBioLab updated the terms of convertible bonds to raise US$5.18M, about 6.4% of its market value.
Capital raise · Sep 22 · 2 versions - [Amended] Material event report (rights offering)
AriBioLab updated the terms of a private placement (third-party allotment) to raise US$13.1M, about 16.5% of its market value.
Capital raise · Sep 16 · 2 versions - Report on large shareholdings (5% rule) (standard)Sep 16
- Material event report (convertible bonds)
AriBioLab disclosed convertible bonds to raise US$2.23M, about 2.8% of its market value.
Capital raise · Sep 14 - [Amended] Share-pledge agreement that may change the largest shareholder
AriBioLab's largest shareholder (Aribio Holdings) pledged shares as loan collateral to a company, securing up to US$2.99M.
Ownership change · Sep 9 · 2 versions - Material event report (rights offering)
AriBioLab disclosed a private placement (third-party allotment) to raise US$1.36M, about 1.8% of its market value.
Capital raise · Jul 23 - [Attachment amended] Material event report (convertible bonds)Capital raise · Jun 22
- [Amended] Material event report (rights offering)
AriBioLab updated the terms of a private placement (third-party allotment) to raise US$1.95M, about 2.8% of its market value.
Capital raise · Jun 22 - [Amended] Material event report (convertible bonds)
AriBioLab updated the terms of convertible bonds to raise US$2.61M, about 3.7% of its market value.
Capital raise · Jun 5 - Share-pledge agreement tied to the largest shareholder terminated/cancelled
A previously disclosed share pledge on AriBioLab's largest shareholder (Solux Co., Ltd.) was released or cancelled, freeing collateral of US$4.17M.
Ownership change · Jun 1 - [Amended] Material event report (rights offering)
AriBioLab updated the terms of a private placement (third-party allotment) to raise US$3.34M, about 4.6% of its market value.
Capital raise · May 29 - [Amended] Material event report (convertible bonds)
AriBioLab updated the terms of convertible bonds to raise US$2.68M, about 3.7% of its market value.
Capital raise · May 28 - Material event report (convertible bonds)
AriBioLab disclosed convertible bonds to raise US$2.68M, about 3.7% of its market value.
Capital raise · May 15 - Share-pledge agreement that may change the largest shareholder
AriBioLab's largest shareholder (Solux Co., Ltd.) pledged shares as loan collateral, securing up to US$4.27M.
Ownership change · Apr 30 - Change of largest shareholderOwnership change · Apr 30
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 10
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 26
- Share transfer agreement that will change the largest shareholder
AriBioLab's controlling stake is set to change hands from CHA Biotech to Solux Co., Ltd. and 3 others, in a deal worth US$15.8M.
Ownership change · Mar 19 - Material event report (rights offering)
AriBioLab disclosed a private placement (third-party allotment) to raise US$3.32M, about 4.6% of its market value.
Capital raise · Mar 19 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 19
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
AriBioLab reported separate results for FY2025: revenue of US$110K (−57.2% year on year), an operating loss of US$9.88M and a net loss of US$11.1M.
Earnings · Feb 12